These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38921800)

  • 41. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
    BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
    Garegnani L; Styrmisdóttir L; Roson Rodriguez P; Escobar Liquitay CM; Esteban I; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013757. PubMed ID: 34783356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
    Yu T; Padula WV; Yieh L; Gong CL
    Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nirsevimab: First Approval.
    Keam SJ
    Drugs; 2023 Feb; 83(2):181-187. PubMed ID: 36577878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
    La Via WV; Notario GF; Yu XQ; Sharma S; Noertersheuser PA; Robbie GJ
    Pulm Pharmacol Ther; 2013 Dec; 26(6):666-71. PubMed ID: 23523663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study.
    Silvestri M; Marando F; Costanzo AM; di Luzio Paparatti U; Rossi GA
    Ital J Pediatr; 2016 Apr; 42():40. PubMed ID: 27112952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF; Sondheimer HM; Tulloh RM; Harris BS; Jensen KM; Losonsky GA; Griffin MP;
    Pediatr Res; 2011 Aug; 70(2):186-91. PubMed ID: 21522037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
    Zylbersztejn A; Almossawi O; Gudka N; Tompsett D; De Stavola B; Standing JF; Smyth R; Hardelid P
    Br J Clin Pharmacol; 2022 Mar; 88(3):1246-1257. PubMed ID: 34478568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.